A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naive myelofibrosis and moderate thrombocytopenia
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Karyopharm Therapeutics
Start Date
August 1, 2024
End Date
July 31, 2029
Administered By
Duke Cancer Institute
Awarded By
Karyopharm Therapeutics
Start Date
August 1, 2024
End Date
July 31, 2029